FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC
Calderasib (MK-1084) received Breakthrough Therapy designation for first-line treatment of KRAS G12C-mutant NSCLC.
Therapeutic Area
Therapeutic area intelligence for KRAS G12C Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.